End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.016 AUD | 0.00% | 0.00% | -20.00% |
Apr. 30 | Transcript : Syntara Limited, Q3 2024 Earnings Call, Apr 30, 2024 | |
Apr. 10 | Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment | MT |
Sales 2024 * | 11.6M 7.62M | Sales 2025 * | 3.6M 2.36M | Capitalization | 19.1M 12.55M |
---|---|---|---|---|---|
Net income 2024 * | -8M -5.25M | Net income 2025 * | -13M -8.54M | EV / Sales 2024 * | 1.03 x |
Net cash position 2024 * | 7.2M 4.73M | Net cash position 2025 * | 9.2M 6.04M | EV / Sales 2025 * | 2.75 x |
P/E ratio 2024 * |
-1.45
x | P/E ratio 2025 * |
-1.78
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.58% |
Latest transcript on Syntara Limited
1 month | -20.00% | ||
3 months | -23.81% | ||
6 months | -46.67% | ||
Current year | -20.00% |
Managers | Title | Age | Since |
---|---|---|---|
Gary Phillips
CEO | Chief Executive Officer | 62 | 03-03-11 |
Director of Finance/CFO | 67 | 02-11-30 | |
Jana Baskar
CTO | Chief Tech/Sci/R&D Officer | - | 22-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Phillips
CEO | Chief Executive Officer | 62 | 03-03-11 |
Director of Finance/CFO | 67 | 02-11-30 | |
Kathleen Metters
CHM | Chairman | 66 | 17-06-06 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-07 | 0.016 | 0.00% | 390,299 |
24-05-06 | 0.016 | +6.67% | 172,688 |
24-05-03 | 0.015 | 0.00% | 1,798,410 |
24-05-02 | 0.015 | -11.76% | 1,245,708 |
24-05-01 | 0.017 | +6.25% | 76,433 |
End-of-day quote Australian S.E., May 06, 2024
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.00% | 12.63M | |
+33.43% | 700B | |
+27.99% | 569B | |
-5.12% | 358B | |
+19.59% | 330B | |
+4.89% | 287B | |
+16.54% | 236B | |
+6.75% | 202B | |
-9.20% | 197B | |
+4.26% | 161B |
- Stock Market
- Equities
- SNT Stock